Labcorp declares $0.72 quarterly cash dividend
Labcorp Holdings Inc. reported that its Board of Directors declared a quarterly cash dividend of $0.72 per share of common stock.
Rhea-AI Filing Summary
Labcorp Holdings Inc. reported that its Board of Directors declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on September 11, 2026 to stockholders of record at the close of business on August 28, 2026.
Labcorp describes itself as a global leader in innovative and comprehensive laboratory services, supporting doctors, hospitals, pharmaceutical companies, researchers, and patients. The company has nearly 71,000 employees, serves clients in approximately 100 countries, supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients worldwide.
Positive
- None.
Negative
- None.
Insights
Labcorp confirms its capital return strategy with a recurring $0.72 quarterly dividend.
The Board of Labcorp Holdings Inc. declared a cash dividend of $0.72 per share, payable on September 11, 2026 to stockholders of record on August 28, 2026. This signals an ongoing commitment to returning cash to shareholders through regular dividends.
The announcement does not change leverage or growth plans by itself, but it reinforces Labcorp’s profile as a mature cash-generating business. The scale of operations—nearly 71,000 employees, activity in about 100 countries, support for more than 85% of FDA-approved new drugs in 2025, and over 750 million tests performed—highlights the operating base that underpins this payout.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Quarterly cash dividend per share: $0.72 per share
Dividend payment date: September 11, 2026
Dividend record date: August 28, 2026
+4 more
7 metrics
Quarterly cash dividend per share
$0.72 per share
Dividend declared by the Board of Directors on common stock
Dividend payment date
September 11, 2026
Payable date for the $0.72 per-share cash dividend
Dividend record date
August 28, 2026
Stockholders of record on this date will receive the dividend
Employees
Nearly 71,000
Global workforce serving clients in approximately 100 countries
Countries served
Approximately 100
Geographic reach of Labcorp’s laboratory services
Share of FDA-approved new drugs supported
More than 85%
Portion of new drugs and therapeutic products approved by the FDA in 2025 supported by Labcorp
Tests performed
More than 750 million
Number of tests performed for patients around the world
Key Terms
cash dividend, stockholders of record, laboratory services, therapeutic products
4 terms
cash dividend financial
"has declared a cash dividend of $0.72 per share of common stock"
A cash dividend is a payment made by a company to its shareholders directly in money, usually on a regular schedule. It is a way for investors to receive a portion of the company's profits, similar to earning interest or a bonus for holding the company's stock. Cash dividends provide income to shareholders and can indicate the company's financial health and stability.
stockholders of record financial
"to stockholders of record as of the close of business on August 28, 2026"
Stockholders of record are the people or entities whose names appear on a company's official shareholder list on a specific cutoff date set by the company or its transfer agent; only those listed are entitled to receive dividends, vote at shareholder meetings, or participate in other corporate actions. Think of it like a guest list for an event: being on the list on the set day determines who gets the benefits and rights, so investors must own shares before the cutoff to qualify.
laboratory services technical
"a global leader of innovative and comprehensive laboratory services"
therapeutic products medical
"supported for more than 85% of the new drugs and therapeutic products approved"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What dividend did Labcorp Holdings Inc. (LH) declare in July 2026?
Labcorp’s Board declared a cash dividend of $0.72 per share of common stock. This quarterly dividend is part of the company’s ongoing capital return to shareholders.
What is the record date for Labcorp’s (LH) September 2026 dividend?
The record date for Labcorp’s $0.72 per share dividend is August 28, 2026. Investors listed as stockholders of record at the close of business that day will be eligible.
How large is Labcorp’s (LH) global operation supporting this dividend?
Labcorp reports nearly 71,000 employees, serving clients in approximately 100 countries. It performed over 750 million tests and supported more than 85% of FDA-approved new drugs in 2025.
What type of services does Labcorp (LH) provide alongside paying dividends?
Labcorp offers innovative and comprehensive laboratory services, supporting doctors, hospitals, pharmaceutical companies, researchers, and patients with diagnostics and drug development capabilities used worldwide.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
(Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| , | ||||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(Registrant’s telephone number including area code) 336 -229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01. | Regulation FD Disclosure. | ||||
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced on July 9, 2026, that its Board of Directors (Board) has declared a cash dividend in the amount of $0.72 per share of common stock. The dividend will be payable on September 11, 2026, to stockholders of record as of the close of business on August 28, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.
| Item 9.01. | Financial Statements and Exhibits. | |||||||
| Exhibit | Exhibit Name | |||||||
| Exhibit 99.1 | Press release dated July 9, 2026 issued by Labcorp Holdings Inc. | |||||||
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
| Date: July 10, 2026 | By: | /s/ KATHRYN W. KYLE | ||||||
| Kathryn W. Kyle | ||||||||
| Executive Vice President, Chief Legal Officer and Corporate Secretary | ||||||||
FOR IMMEDIATE RELEASE
| Media | Investors | |||||||
| Racquel White | Dewey Steadman | |||||||
| Media@Labcorp.com | Investor@Labcorp.com | |||||||
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., July 9, 2026 - Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2026, to stockholders of record as of the close of business on August 28, 2026.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.